Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
By Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, J. W. Chapman, D. Niedzwiecki, V. Suman, J. Moon, V. Sondak, M. Atkins, E. Eisenhauer and 4 more. Journal of Clinical Oncology, 2008
685 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/bc98dc97057d8487b63f8a522273ce724e9a5a75
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
- Padmanee Sharma
- James P. Allison
- J. Wolchok
- Antoni Ribas
- Lieping Chen
- Eleftherios P. Diamandis
- S. Farkona
- I. Blasutig
Citations in the corpus
- Increasing burden of melanoma in the United States (2009, neutral): “…survival for late-stage melanoma in the United States has not changed appreciably over the past 30 years (Barth et al., 1995), nor have there been any major innovations in melanoma 1670 Journal of Investigative Dermatology (2009), Volume 129 www.jidonline.org 1671 treatment (Korn et al., 2008).”
- Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011, result): “This was a dramatic improvement in the survival of patients with metastatic melanoma compared to a previously published meta-analysis that indicated that only 25% of patients with metastatic melanoma lived for 1 yea”